Adaptive Biotechnologies (ADPT) revenue and earnings history
Adaptive Biotechnologies reported revenue of $277M for fiscal 2025 (year ended Dec 31, 2025), +54.8% on the year before, and net income of −$59.5M.
Over 8 years, from fiscal 2017 to fiscal 2025, revenue grew at a compound rate of +28.0% a year.
Revenue and net income, 9 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $277M+54.8% | −$57.1M | −$59.5M | −$46M | $2.96M | −$48.9M | $51.5M | — | — | $70.5M | $131M | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Adaptive Biotechnologies (ADPT) on OQRO.
Common questions
What was Adaptive Biotechnologies's revenue in fiscal 2025?
$277M for the year ended Dec 31, 2025, as reported in its 10-K filed Feb 26, 2026. That is +54.8% on fiscal 2024 ($179M).
How fast has Adaptive Biotechnologies's revenue grown?
From $38.4M in fiscal 2017 to $277M in fiscal 2025: a compound annual growth rate of +28.0% over 8 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Adaptive Biotechnologies tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
